4//SEC Filing
Deerfield Private Design Fund III, L.P. 4
Accession 0001193805-19-000117
CIK 0001346302other
Filed
Feb 6, 7:00 PM ET
Accepted
Feb 7, 8:13 PM ET
Size
27.6 KB
Accession
0001193805-19-000117
Insider Transaction Report
Form 4
Flynn James E
10% OwnerOther
Transactions
- Sale
Common Stock
2019-02-06$15.00/sh−400$6,000→ 873,120 total(indirect: Through Deerfield Special Situations Fund, L.P.) - Sale
Common Stock
2019-02-07$15.00/sh−9,409$141,135→ 863,711 total(indirect: Through Deerfield Special Situations Fund, L.P.) - Sale
Common Stock
2019-02-05$15.07/sh−4,998$75,308→ 873,520 total(indirect: Through Deerfield Special Situations Fund, L.P.)
Holdings
- 1,498,666(indirect: Through Deerfield Private Design Fund III, L.P.)
Common Stock
Footnotes (3)
- [F1]The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.13, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt, L.P. is the general partner of Deerfield Special Situations Fund, L.P. (collectively with Fund III, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P.
- [F3]In accordance with Instruction 4(b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Documents
Issuer
XERIS PHARMACEUTICALS INC
CIK 0001346302
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001603333
Filing Metadata
- Form type
- 4
- Filed
- Feb 6, 7:00 PM ET
- Accepted
- Feb 7, 8:13 PM ET
- Size
- 27.6 KB